The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/8862069 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 27.02.2026. Verfasst von Anna Zygmunt und 6 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Androgenetic alopecia involves the gradual miniaturization of hair follicles, resulting in progressive hair loss. Despite its prevalence, it remains a therapeutic challenge. Current treatments, such as minoxidil and oral finasteride, have limitations. Botulinum toxin type A (BTXA) offers a complementary approach by relaxing scalp muscles, potentially improving blood flow and prolonging hair follicle lifespan.
Objectives
This review aims to evaluate the therapeutic potential of BTXA in AGA treatment by analyzing recent literature. The primary focus is to assess BTXA’s effectiveness, underlying mechanisms, and safety as an adjunctive therapeutic option.
Methods
A systematic search of PubMed identified studies on BTXA for AGA from the database’s inception to December 2024. Emtree and MeSH terms such as “Botulinum Toxins, Type A” and “Androgenetic Alopecia” were used along with additional combinations designed to thoroughly identify relevant studies in the field. Eleven studies met PRISMA guidelines and predefined inclusion and exclusion criteria.
Results
BTXA treatment proved effective in androgenetic alopecia, increasing hair density by 13%–20% within 12–24 weeks ( p < 0.05) and improving follicle diameter by 3 months ( p < 0.001). It reduced DHT‐induced apoptosis in dermal papilla cells via anti‐inflammatory mechanisms and improved seborrhea and scalp vascularization with no significant adverse effects, supporting its role as a safe adjunctive therapy.
Conclusions
BTXA improves hair density and follicle health in AGA through enhanced vascular dynamics and anti‐inflammatory actions. It is a promising adjunctive therapy requiring further studies to refine protocols and assess long‐term outcomes.
Zitieren
APA
Zygmunt, A., Mandecka, A., Karoń, Ł., Leonik, S., Kruczek, W., Frątczak, A., & Bergler-Czop, B. (2026). The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/8862069
Vancouver
Zygmunt A, Mandecka A, Karoń Ł, Leonik S, Kruczek W, Frątczak A, et al. The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/8862069
BibTeX
@article{Zygmunt2026,
author = {Zygmunt, Anna and Mandecka, Anna and Karoń, Łukasz and Leonik, Szymon and Kruczek, Wiktor and Frątczak, Aleksandra and Bergler-Czop, Beata},
title = {The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/8862069}
}
EUVIMED